Edition:
United Kingdom

Insmed Inc (INSM.OQ)

INSM.OQ on NASDAQ Stock Exchange Global Select Market

14.64USD
14 Dec 2018
Change (% chg)

$-0.42 (-2.79%)
Prev Close
$15.06
Open
$15.00
Day's High
$15.00
Day's Low
$14.44
Volume
231,716
Avg. Vol
327,580
52-wk High
$33.94
52-wk Low
$13.86

Chart for

About

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $2,392.91
Shares Outstanding(Mil.): 76.50
Dividend: --
Yield (%): --

Financials

  INSM.OQ Industry Sector
P/E (TTM): -- 69.71 34.39
EPS (TTM): -3.04 -- --
ROI: -92.57 9.01 14.96
ROE: -112.72 10.15 16.52

Insmed's treatment-resistant lung disease drug gets FDA approval

The U.S. Food and Drug Administration on Friday approved Insmed Inc's lead drug to treat a rare, chronic lung disease, making it the first approved treatment in the United States for the condition.

28 Sep 2018

UPDATE 1-Insmed's treatment-resistant lung disease drug gets FDA approval

Sept 28 The U.S. Food and Drug Administration on Friday approved Insmed Inc's lead drug to treat a rare, chronic lung disease, making it the first approved treatment in the United States for the condition.

28 Sep 2018

Insmed's treatment-resistant lung disease drug gets FDA approval

Sept 28 The U.S. Food and Drug Administration on Friday approved Insmed Inc's lead drug to treat a rare, chronic lung disease, making it the first approved treatment in the United States for the condition.

28 Sep 2018

Earnings vs. Estimates